Adcendo ApS to Participate in Upcoming September Investor Conferences

Copenhagen, Denmark, Aug. 27, 2025 — Adcendo, a clinical-stage biotech company pioneering the development of first- and best-in-class antibody-drug conjugates (ADCs) for cancers with a high unmet medical need, today announced that management will participate in five upcoming investor conferences in September:

• Citi 2025 Biopharma Back-to-School Conference
  Format: 1×1 meetings
  Date: Tuesday, September 2, 2025
  Location: Boston, MA
• Wells Fargo 2025 Healthcare Conference
  Format: Company presentation
  Date: Wednesday, September 3, 2025
  Time: 3:45 p.m. ET
  Location: Boston, MA
• Cantor Global Healthcare Conference
  Format: 1×1 meetings
  Date: Thursday, September 4, 2025
  Location: New York, NY
• Morgan Stanley 23rd Annual Global Healthcare Conference
  Format: Company presentation
  Date: Monday, September 8, 2025
  Time: 1:50 p.m. ET
  Location: New York, NY
• Bank of America Healthcare Trailblazers Private Company Conference
  Format: 1×1 meetings
  Date: Wednesday, September 17, 2025
  Location: Boston, MA

About Adcendo

Adcendo is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first-in-class ADCs targeting cancers with high unmet medical needs. Led by a team of industry veterans with a track record of advancing multiple ADCs to approval, Adcendo integrates novel targets, optimized linker-payload combinations, and a rationally designed development strategy to drive next-generation cancer therapies. For further information, please visit www.adcendo.com or follow the company on LinkedIn.

Logo: https://mma.prnewswire.com/media/2758713/Adcendo_Logo.jpg